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Sialylation converts arthritogenic IgG into inhibitors
of collagen-induced arthritis
Yuhsuke Ohmi1,2, Wataru Ise3,*, Akira Harazono4,*, Daisuke Takakura5, Hidehiro Fukuyama6, Yoshihiro Baba3,
Masashi Narazaki7, Hirofumi Shoda8, Nobunori Takahashi9, Yuki Ohkawa1,10, Shuting Ji1, Fumihiro Sugiyama11,
Keishi Fujio8, Atsushi Kumanogoh7, Kazuhiko Yamamoto8, Nana Kawasaki4,5, Tomohiro Kurosaki3,6,
Yoshimasa Takahashi2 & Koichi Furukawa1,10
Rheumatoid arthritis (RA)-associated IgG antibodies such as anti-citrullinated protein
antibodies (ACPAs) have diverse glycosylation variants; however, key sugar chains
modulating the arthritogenic activity of IgG remain to be clariﬁed. Here, we show that
reduced sialylation is a common feature of RA-associated IgG in humans and in mouse
models of arthritis. Genetically blocking sialylation in activated B cells results in exacerbation
of joint inﬂammation in a collagen-induced arthritis (CIA) model. On the other hand, artiﬁcial
sialylation of anti-type II collagen antibodies, including ACPAs, not only attenuates
arthritogenic activity, but also suppresses the development of CIA in the antibody-infused
mice, whereas sialylation of other IgG does not prevent CIA. Thus, our data demonstrate that
sialylation levels control the arthritogenicity of RA-associated IgG, presenting a potential
target for antigen-speciﬁc immunotherapy.
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R
heumatoid arthritis (RA) is a chronic autoimmune disorder
characterized by joint destruction and inﬂammation.
Although the combination of biologic and conventional
synthetic disease-modifying anti-rheumatic drugs has improved
the quality of life for patients with RA, profound remission is
only achieved by 5–10% of treated patients1. Moreover, because
current treatments are based on antigen-non-speciﬁc suppression
of immune responses, concomitant suppression of protective
immunity to infectious pathogens may increase the risk of
adverse effects. Therefore, new immunomodulatory therapies are
needed to selectively target RA-associated autoimmune reactions.
Development of antigen-speciﬁc therapy for RA has been
hampered by insufﬁcient knowledge of the autoimmune reactions
underlying disease pathogenesis. Previous studies have identiﬁed
autoantigens and autoantibodies that are potentially relevant to
RA pathogenesis. Among them, anti-citrullinated protein anti-
bodies (ACPAs) are highly speciﬁc to RA patients and are applied
as the most speciﬁc biomarker for diagnosis and prognosis
prediction2,3. Moreover, several clinical observations indicate the
pathogenic potential of ACPAs: the presence of synovial
ACPAs precedes the clinical manifestations of arthritis4–6, and
ACPAþ immune complexes promote proinﬂammatory cytokine
secretion by macrophages7. Furthermore, the osteoclastogenic
ability of ACPAs and the immune complexes can contribute to
RA pathogenesis8,9. Indeed, the arthritogenic activity of ACPAs
was demonstrated in a mouse model of RA in which passive
transfer of mouse ACPAs induced inﬂammatory arthritis with a
clinical signature comparable to that of human RA10,11, although
such arthritogenic activity is observed not only in ACPAs, but
also in collagen-binding antibodies. Thus, further understanding
of autoantibody-mediated RA pathogenesis would accelerate
the development of novel antigen-speciﬁc immunotherapies for
RA-associated joint destruction and inﬂammation.
Autoantibodies including ACPAs are typically of the IgG
isotype, which carry one conserved N-glycosylation site at
Asn297 on each of their Fc regions12. Intriguingly, patients
with progressive RA have poorly galactosylated and sialylated
IgG compared with patients with less severe disease or
those in remission13–16. Degalactosylated IgG enhance
pathogenic activity in several autoimmune disease models17,18.
Conversely, galactosylated IgG counteract complement-mediated
inﬂammation19, supporting the concept that galactosylation levels
inﬂuence the pathogenic potential of IgG. Likewise, sialylation of
IgG Fc confers regulatory function on disease-associated
antibodies, whereas non-sialylated IgG exaggerates antigen-
dependent inﬂammation20,21. Also, Ravetch et al. reported that
the sialylated fraction of intravenous immunoglobulin G (IVIG) is
effective in its anti-inﬂammatory activity22, although sialylation-
independent effects have also been observed23,24. Therefore,
modulation of glycosylation on disease-associated IgG might be
vital to develop an immunomodulatory therapy that selectively
targets disease-associated autoimmune reactions.
Here we show that the sialylation process contributes to disease
pathogenesis in the collagen-induced arthritis (CIA) mouse
model, a model that mirrors many clinical and immunological
features of RA. Enforced sialylation of mouse collagen antibodies,
including ACPAs, reverses proinﬂammatory activity and provides
a regulatory function in CIA, whereas the sialylation of other IgG
was not preventive of disease. Thus, the sialylation of IgG Fc
converts ACPAs from a ‘pathogenic’ form to a ‘regulatory’ form,
providing a feasible approach to control RA pathogenesis.
Results
IgG Fc is desialylated in RA patients. Human and murine IgG of
all subclasses have a conserved N-glycosylation site at Asn297 on
their Fc regions (Fig. 1a). N-glycans on IgG Fc have been
classiﬁed into three subgroups: the ﬁrst ending with
N-acetylglucosamine (GlcNAc) (G0F), the second with galactose
on one arm (G1F) and the third with two galactose on both arms
(G2F) (Fig. 1a). A minor fraction of galactosylated glycan can be
further sialylated with either one (G1FS1 or G2FS1) or two sialic
acid residues (G2FS2) (Fig. 1a). Agalactosylated glycoforms (G0F)
are frequently observed in serum IgG of RA patients13,16.
Likewise, agalactosylated glycoforms are observed in murine
IgG in autoimmune-prone mouse strains such as the MRL/lpr
strain25,26; however, the glycosylation proﬁles of RA-associated
IgG have not been directly compared in RA patients and mouse
models. We assessed RA-associated glycosylation proﬁles on IgG
ACPA and total IgG in ACPAþ RA patients. ACPAþ RA
patients showed high amounts of cyclic citrullinated peptide
(CCP)-binding IgG (ACPA) but normal total IgG levels in their
serum (Fig. 1b). Three types of IgG fractions were puriﬁed and
subjected to liquid chromatography-electrospray ionization-mass
spectrometry (LC-ESI-MSI) analysis: serum ACPA puriﬁed by
the binding ability to CCP from ACPAþ RA patients (ACPA/
RA), total serum IgG deprived of ACPA from the same RA
patients (FT/RA), and total serum IgG from healthy donors
(total/HD) (Fig. 1c; Supplementary Fig. 1). To assess the antigen
speciﬁcity of puriﬁed ACPA, the binding of puriﬁed ACPA to
CCP and arginine-control peptide was compared in parallel
(Supplementary Fig. 1). We observed that the binding of puriﬁed
ACPA to the control peptide was 100-fold lower than that
to CCP. Moreover, a competitive ELISA (enzyme-linked
immunosorbent assay) conﬁrmed the lack of binding to the
control peptide because CCP binding of the puriﬁed ACPA was
blocked by the addition of CCP but not by control peptide.
However, low recovery of antibodies from ACPA-negative RA
patients suggests that small amounts of non-ACPA is included in
ACPA fraction through the puriﬁcation process as previously
noted27 (Supplementary Fig. 2).
Consistent with previous reports16, the frequencies of
terminally sialylated glycoforms, G1FS1 (peak 1), G2FS1
(peak 2), and G2FS2 (peak 4) were equivalently reduced in
both IgG1 ACPA and total IgG1 from RA patients compared with
total IgG1 from healthy donors; no difference was found between
ACPA and total IgG1 from RA patients (Fig. 1d). As sialic acid
is covalently attached to galactose, reduced sialylation may
represent either a lack of sialic acid itself (Fig. 1a, arrow 1) or a
lack of galactosylation (Fig. 1a, arrow 2). To discriminate between
these possibilities, we analysed the ratios of galactosylated G1F
(peak 11) and G2F (peak 15) glycoforms per G0F backbone
(peak 8). The frequency of galactosylation was reduced in both
ACPA and total IgG1 in RA patients to levels comparable to those
with terminal sialylation (Fig. 1e). In fact, galactose-containing
glycoforms were equivalently sialylated in all three types of IgG1
(Supplementary Fig. 3). Therefore, these results indicate that the
reduced sialylation of Fc primarily reﬂects a lack of galactose
rather than defective terminal sialylation. Glycosylation proﬁles of
IgG2 subclass were consistent with those observed for IgG1,
indicating that this is a common event in all IgG classes
(Supplementary Fig. 4). It is unlikely that the contaminating
non-ACPA antibodies affect the results, because the removal of
non-speciﬁc antibodies using an arginine-control-peptide-coated
column did not demonstrate any difference in the glycan proﬁles
(Supplementary Fig. 5).
IgG Fc is desialylated in arthritis mouse models. The
glycosylation proﬁles of antigen-speciﬁc and total IgG1 were
assessed in a CIA mouse model after immunization with
adjuvanted type II collagens (Col II). We used highly susceptible
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Figure 1 | IgG Fc in RA patients is desialylated because of lack of galactosylation. (a) Structure of N-glycosylation forms attached to Asn297 in the IgG
Fc portion. Sugar chains of IgG comprise bi-antennary chains, and are further modiﬁed by binding bisecting N-acetylglucosamine (GlcNAc), core-
fucosylation and terminal a2,6-linkage of sialic acid to galactose. Sia, sialic acid; Gal, galactose; Man, mannose; Fuc, fucose. (b) CCP-binding IgG (ACPA)
titres and total IgG levels from RA patients (n¼ 17) or healthy donors (n¼ 12) are presented. Each symbol represents the data from an individual donor.
Mean values were presented as bars. ND, not detectable. (c) LC-ESI-MS analysis of IgG1 Fc glycans in total IgG from HDs (Total/HD), and those in the
ﬂow-through (FT) of CCP columns (FT/RA) and CCP-binding IgG ACPA (ACPA/RA) from RA patients. Glycoforms of human IgG1 Fc are shown in
Supplementary Table 1. pep, peptide moiety (EEQYNSTYR). (d,e) Ratios of sialylated (d) and galactosylated (e) IgG Fc glycans to agalactosylated IgG Fc
glycan (G0F) in each group of serum were calculated and plotted. Each circle represents the result from an individual donor. Mean values were presented
as bars. Data were analysed by Steel–Dwass non-parametric test (**Po0.01; ***Po0.001).
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DBA/1 strains, all of which developed joint inﬂammation after
booster immunization (Fig. 2a). Although the CIA mouse model
is widely used to mimic the antibody-dependent process of RA
pathogenesis, conﬂicting reports on ACPA induction in this
mouse model exist10,28. Indeed, at least in the experimental
conditions deﬁned by us, ACPAs were produced at insufﬁcient
levels for glycosylation proﬁling by mass spectrometry (Fig. 2b).
Hence, anti-Col II IgG antibodies, which have arthritogenic
activity29–31, were puriﬁed for glycosylation proﬁling
(Supplementary Fig. 6). We prepared four types of serum IgG
fractions for LC-ESI-MS analysis: anti-Col II antibody from CIA
mice (aCol II/CIA), total IgG deprived of anti-Col II antibody
from the same mice (FT/CIA) and total serum IgG from CFA
primed (total/CFA) or naive mice (total/naive) (Fig. 2c;
Supplementary Fig. 6b,c). The ratios of sialylated glycoforms
were signiﬁcantly reduced in anti-Col II and total IgG1 of CIA
mice relative to naive mice; the reduction was signiﬁcantly
exaggerated in bi-galactosylated forms of anti-Col II IgG1
(Fig. 2d). Sialylation was also reduced in total IgG1 from CFA-
injected mice, albeit at an insigniﬁcant level. The glycoforms
containing terminal galactose residues were comparable among
the four groups in non-CIA and CIA mice (Fig. 2e) and similar
results were obtained for IgG2a/b subclasses (Supplementary
Fig. 7). Thus, these results indicate that poor sialylation of IgG Fc
is a feature common to both RA patients and CIA mice, although
the underlying mechanisms may not be identical.
Because CIA mouse model do not completely replicate RA in
humans, we decided to analyse another RA model mice which
express human HLA-DR4 known to be associated with RA32,33.
Immunization of this mouse strain with citrullinated ﬁbrinogen
(cFib) induces joint inﬂammation concomitant with the induction
of cFib-speciﬁc B- and T-cell responses, mimicking clinical and
immunological features of RA patients (Supplementary Fig. 8a).
However, similar to that observed with the previous CIA model,
ACPAs were again produced at insufﬁcient levels for glycosylation
proﬁling. Therefore, following RA induction, we puriﬁed three
types of serum IgG fractions for LC-ESI-MS analysis: anti-Fib
antibody from cFib-immunized mice (Fib/cFib), total IgG deprived
of anti-Fib antibody in the same mice (FT/cFib) and total IgG from
naı¨ve mice (total/naive) (Supplementary Figs 8 and 9). As observed
for the CIA model, sialylated IgG1 was signiﬁcantly reduced in
cFib-immunized transgenic mice compared with naive transgenic
mice, but the galactosylation level was comparable (Supplementary
Figs 9 and 10). Thus, the comparative glycosylation proﬁling of RA
patients and two independent mouse models indicates that
desialylation of IgG Fc is associated with RA disease in both
species, although the changes in Fc-sialylation are also observed in
other inﬂammatory conditions34.
Loss of sialylation exacerbates joint inﬂammation in CIA. The
elevated levels of desialylated IgG observed in RA patients and
mouse models led us to investigate the direct link between desia-
lylated IgG and the progression of RA pathogenesis. While dega-
lactosylated IgG has been suggested to exacerbate the pathogenesis
of RA17, the role of desialylated IgG in the RA mouse model has
not been addressed. Here, we utilized a gene-targeting approach to
block the sialylation of endogenously produced IgG. Sialylation of
IgG Fc is carried out by the glycosyltransferases, namely, ST6Gal1
and/or ST6Gal2, that catalyse the transfer of a sialic acid to
galactose with a2,6-linkage. The expression level of mSt6gal2 gene
was much lower than mSt6gal1 in all tissues examined
(Supplementary Fig. 11). Therefore, we crossed ST6Gal1f/f with
mice expressing Cre recombinase under the control of activation-
induced cytidine deaminase gene promoter (AID-Cre) (ref. 35)
(Supplementary Fig. 12), which is selectively activated in
stimulated B cells. Both homozygous (ST6Gal1f/f AID-Creþ )
and control AID-Cre (ST6Gal1þ /þ AID-Creþ ) mice were
immunized with adjuvanted chicken Col II twice to induce CIA
(Fig. 3a). To assess the sialylation levels of serum IgG in these mice,
we puriﬁed both anti-Col II IgG and total IgG from each genotype
of mice after CIA induction. Sambucus nigra (SNA) lectin blot and
MALDI-TOF-MS analysis revealed the reduced sialylation of total
IgG from ST6Gal1 / and ST6Gal1f/f AID-Cre mice, conﬁrming
the major contribution of ST6Gal1 to IgG Fc-sialylation (Fig. 3b;
Supplementary Figs 13 and 20). We then analysed anti-Col II IgG
titres in CIA mice and observed that homozygous mice produced
comparable levels of anti-Col II IgG after priming and boosting of
Col II, although total IgG levels were slightly but signiﬁcantly
reduced in homozygous mice (Fig. 3c; Supplementary Fig. 14).
Therefore, deﬁcient ST6Gal1 expression in activated B cells did
not cause severe defects in B-cell pathways for arthritis-associated
IgG production. However, despite equivalent production of
arthritis-associated IgG, homozygous mice developed CIA at
earlier time points and exhibited a 42-fold higher incidence of
CIA compared with control mice (Fig. 3d). More severe joint
swellings or ankylosis of the limb were also observed in
homozygous mice (Fig. 3e). These data clearly demonstrate that
sialylation levels of activated B-cell-intrinsic molecules regulate
joint inﬂammation. Although there are several other candidate
molecules (i.e., cytokines) that may be involved in this process,
here we focused on sialylation levels of IgG Fc as the reduced
sialylation of IgG Fc was common feature in RA patients and
mouse models (Figs 1–3).
Sialylation diminishes the arthritogenic activity of ACPAs.
ACC4 monoclonal antibody is a mouse ACPA (IgG1) that binds
citrullinated Col II, and infusion of this antibody frequently
induces collagen antibody-induced arthritis (CAIA) in the
presence of the anti-Col II monoclonal antibody M2139
(IgG2b)11. To produce sialylated forms of these antibodies, both
mSt6gal1 and mB4galt1 cDNAs were transfected into ACC4 and
M2139 hybridomas (Fig. 4a). The majority of terminal sugars of
IgG Fc from double-transfected ACC4 and M2139 hybridoma
cells were found to extend to a2,6 sialic acid (G2FS2), whereas
those from non-transfected ACC4 and M2139 hybridoma cells
were ended with terminal galactose or GlcNAc (G0F or G1F)
(Fig. 4b; Supplementary Fig. 15). SNA lectin blot analysis also
supported increased Fc-sialylation in the transfectants, whereas
SNA binding of the Fab fragment remained unaffected
(Supplementary Fig. 16). SNA lectin recognizes Neu5Ac
(a2–6)Gal/GalNAc residue found in N-linked and O-linked
glycans36,37; however, the removal of N-linked glycans by
PNGase F treatment selectively abolished SNA binding to the
Fc fragment, but not to the Fab fragment even under SDS
denaturation (Supplementary Fig. 17). The lack of sequence motif
for N-linked glycosylation site (N-X-S/T, X is any residues except
proline) in the ACC4 Fab domain further supported that SNA
binding to the Fab fragment is mediated by either O-linked
glycans or other unidentiﬁed molecules, rather than by N-linked
glycans. Thus, the overexpression of mSt6gal1 and mB4galt1
produced IgG antibodies with increased sialylation in an
Fc-speciﬁc manner. Sialylation of both monoclonal antibodies
showed no signiﬁcant impact on the binding ability to antigens
(Fig. 4c). To elucidate the arthritogenic activity of sialylated
antibodies, we administered ACC4/M2139 IgG-Sia (þ ) or
ACC4/M2139 IgG into DBA/1 mice to induce CAIA (Fig. 4d).
As previously reported, the infusion of ACC4/M2139 IgG
induced CAIA in approximately half of DBA/1 mice11.
However, ACC4/M2139 IgG-Sia (þ ) failed to induce CAIA in
all mice (Fig. 4e). Likewise, histopathological analysis of the
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joints revealed no signs of inﬂammation in mice infused with
ACC4/M2139 IgG-Sia (þ ), whereas those with ACC4/M2139
IgG showed the expected arthritis phenotype, i.e., inﬁltration of
monocytes, lymphocytes and granulocytes (Fig. 4f). These results
clearly demonstrate that sialylation reduces the pathogenicity of
anti-Col II antibodies, including ACPAs.
Sialylated anti-Col II antibody exhibits regulatory activity.
Sialylation has been shown to enhance the regulatory activity of
IVIG in a K/BxN serum-mediated arthritis model22. This
prompted us to assess the regulatory activity of sialylated
ACPAs in the RA model. We utilized the CIA model because
this model mimics both early autoimmune responses and later
antibody-dependent effector phase that triggers the development
of joint inﬂammation. In these experiments, some groups of mice
were infused with a cocktail of ACC4/M2139 antibody with or
without sialylation one day before boosting for CIA induction
(Fig. 5a). Although the infusion of sialylated ACC4/M2139
antibodies reduced the incidence of CIA and that of
control antibodies increased the incidence, the difference did
not reach statistical signiﬁcance (Fig. 5b). However, mice treated
with sialylated antibodies showed signiﬁcantly milder arthritis
scores than untreated mice or those treated with control
antibodies (Fig. 5c,d). To estimate whether disease severity
correlates with sialylation levels of anti-Col II IgG antibodies
in serum, we compared the sialylation levels of anti-Col II IgG
from mice infused with ACC4/M2139 (Fig. 5) and ST6Gal1-
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deﬁcient mice (Fig. 3) on day 7 after CIA induction
(Supplementary Fig. 18). Infusion of control ACC4/M2139 did
not alter the sialylation levels of anti-Col II IgG in serum;
however, infusion of sialylated forms of ACC4/M2139
signiﬁcantly increased the sialylation levels of anti-Col II IgG.
Additionally, the sialylation levels of anti-Col II IgG from
ST6Gal1-deﬁcient mice were below the detection limit. The levels
were even lower than those in the control mice without antibody
infusion, consistent with the data depicted in Fig. 3b. Thus,
sialylation not only reduces the arthritogenic activity of anti-Col
II antibodies, including ACPAs, but also induces the regulatory
activity in the CIA model.
Sialylated IVIG inhibits K/BxN serum-induced arthritis and
other autoimmune diseases more potently than non-sialylated
IVIG22,34,38,39. Thus, the observed regulatory effects of sialylated
ACPAs might simply represent antigen-non-speciﬁc processes
as provided by IVIG. To address this issue, we sialylated the
isotype-matched mouse IgG1 antibody, namely, 1E11 (inﬂuenza
hemagglutinin speciﬁc). IgG1 Fc of both ACC4 and 1E11
were heavily sialylated to similar levels after the introduction
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of mSt6gal1 and mB4galt1 genes into the hybridomas
(Supplementary Fig. 19). Sialylated ACPA or irrelevant IgG
(1E11) was co-infused with M2139 and the regulatory activity
of these antibodies was examined (Fig. 5e). M2139 was used
in both infusions so that the speciﬁc effect of the ACPA could
be evaluated. Strikingly, a cocktail of sialylated 1E11/M2139
did not show any regulatory activity at all, while that of sialylated
ACC4/M2139 did, as measured by the severity of the arthritis
score (Fig. 5f). Thus, these data demonstrate that the
regulatory activity shown by sialylated ACPA is based on an
antigen-speciﬁc event.
Discussion
Many pieces of clinical evidence suggest a pathogenic role for
ACPAs in RA. Before the onset of arthritis, ACPAs display
several unique features that are potentially involved in disease
pathogenesis, including degalactosylation of IgG Fc, reduced
afﬁnity maturation and epitope spreading40–42. Unfortunately,
there is no RA mouse model available to completely mimic
ACPA-mediated RA pathogenesis. Therefore, we evaluated the
pro- and anti-inﬂammatory functions of IgG Fc glycans in CIA
mouse model, and found that sialylation level is crucial in the
control of RA pathogenesis. Furthermore, highly sialylated
collagen antibodies including ACPA was successfully applied as
an immunosuppressive drug ameliorating joint inﬂammation in
an CIA mouse model. Thus, the modulation of Fc glycosylation
patterns of RA-associated IgG may be a key target for the
development of antigen-speciﬁc immunotherapies for RA.
Pro- and anti-inﬂammatory functions of IgG Fc with different
sialylation patterns have been addressed in antibody infusion
systems which mirror the effector function of IgG-mediated
inﬂammatory diseases, including RA19,22,34,43–47. However,
because of the lack of other autoimmune components, this
system does not replicate all features of RA pathogenesis. Here,
we tested a genetic approach, in which the sialylation of
endogenous IgG was blocked by conditional ST6Gal1
deﬁciency. The function of IgG sialylation was assessed in the
CIA mouse model where pathogenic antibodies are produced
along with other important autoimmune components. We noted
that desialylation exacerbated RA joint inﬂammation without
affecting antigen-speciﬁc IgG production; therefore, severe
bystander effects on antigen-speciﬁc B-cell development were
unlikely. Thus, our data strongly support a proinﬂammatory
function of desialylated IgG on the development of RA.
Although RA patients showed reduced galactosylation and a
resulting reduction of sialylated forms, two mouse RA models
showed a speciﬁc reduction in sialylation, but not in galactosyla-
tion. In the absence of animal models with an appropriate
genetic background and autologous Col II, it is difﬁcult to fully
reproduce the long-lasting chronic inﬂammation observed in RA
patients48,49. Therefore, the differential IgG glycosylation
patterns between RA patients and mouse models may be the
result of long-term chronic exposure to inﬂammation in RA
patients, leading to broader effects on the glycosylation state
of immune cells. A key enzyme for IgG galactosylation is B4-
galactosyltransferase (GTase)50 which exists in both intracellular
and extracellular compartments51–53. Intracellular GTase activity
was signiﬁcantly reduced in lymphocytes from RA patients, in a
manner proportional to disease severity54, suggesting that
long-lasting chronic inﬂammation may cause a reduction in
GTase levels in B cells and promote the degalactosylation of IgG.
In any case, the consequences of both degalactosylation and
desialylation manifest as reduced sialylation, which we show is
sufﬁcient to exacerbate RA pathogenesis. However, it is still
possible that degalactosylation itself can increase the
proinﬂammatory activity of human ACPAs through pathways
other than desialylation in RA patients.
Importantly, sialylated ACPAs acquired regulatory activity in
CIA in an antigen-speciﬁc manner, while the sialylation of
irrelevant IgG was non-preventive. It should be stressed that
ACPAs, but not irrelevant IgG, are able to react with citrullinated
proteins in the joints10; therefore, it is expected that sialylated
ACPAs would be more concentrated in diseased tissue. In line
with this, we propose three possible models: (1) competition for
antigen-binding sites with desialylated ACPA that trigger
inﬂammatory reactions by binding to ‘activating’ FcgRs or
analogous receptor molecules in the joints (space competition
model), (2) direct activation of inhibitory FcgRIIb on joint
macrophages (direct suppression model) and (3) indirect
induction or activation of inhibitory FcgRIIb via other ligand
molecules or ligand-expressing cells present in the joints, as
observed for anti-inﬂammatory activity of IVIG (indirect
suppression model)44. The ﬁrst model is supported by previous
ﬁndings that sialylation of IgG reduced the binding afﬁnity to all
activating FcgRs43,44; thus, the replacement of local ACPAs by
sialylated types would reduce the average pathogenic activity of
local ACPAs. The third model is analogous to the model
proposed by Ravetch’s group in which the systemic
anti-inﬂammatory effects of sialylated IVIG are mediated by
binding to SIGN-R1 (DC-SIGN in humans) on marginal zone
macrophages, and subsequent up-regulation of FcgRIIb on
inﬂammatory macrophages44.
An important question remains: how can the sialylation levels
of ACPAs be modulated clinically. As shown in this study, one
key target molecule is ST6Gal1. This enzyme is ubiquitously
expressed in many cell types, including plasma cells20; however, it
is important to note that ST6Gal1 expression in plasma cells is
inﬂuenced by the types of antigens and immunization
protocols20,21. In particular, antigens or immunization regimes
that do not activate T cells maintain ST6Gal1 expression in
plasma cells, leading to the production of highly sialylated IgG,
whereas B-cell activation in the presence of T cell turns off the
expression of this enzyme21. If this is the case during the
developmental of IgG ACPAs, then T-cell-independent activation
of ACPAþ B cells may be a better approach to suppress RA-
speciﬁc inﬂammation rather than the current B-cell depletion
protocols.
Methods
Patients. Blood samples from clinically deﬁned ACPAþ or ACPA RA patients
and from healthy donors were collected in Osaka University Hospital, Nagoya
University Hospital and University of Tokyo Hospital. Written informed consent was
obtained from all participants. This study was approved by the ethical committees of
Nagoya University, Osaka University, University of Tokyo, National Institute of
Infectious Diseases, National Institute of Health Sciences, and RIKEN Center for
Integrative Medical Sciences. Sera were isolated from the blood samples by using
Ficoll-Paque PLUS (GE Healthcare Ltd., Chalfont St Giles, UK) with ﬁbrinogen
removed using rapid clotting tubes (NIPRO, Osaka, Japan), and stored at  80 C.
Mice. Male DBA/1 and C57BL/6 mice (8-week old) were obtained from SLC Inc.
(Hamamatsu, Japan). Transgenic mice expressing Cre recombinase under the
control of activation-induced cytidine deaminase gene promoter (hereafter,
AID-Cre mice) were provided by R. Casellas (National Institute of Arthritis and
Musculoskeletal and Skin Diseases). HLA-DR4 transgenic mice were obtained from
Taconic Biosciences. All experimental protocols were approved by the animal
experimental committees of the Graduate School of Medicine in Nagoya University
and Osaka University.
Generation of ST6Gal1f/f AID-Cre mice. To generate ST6Gal1f/f AID-Cre mice,
three fragments were subcloned from mSt6gal1 locus in C57BL/6 strain-derived
RPCI23.C BAC clone (ID, 215I11) and these were inserted into a targeting vector
containing three loxP sites, two FRT sites and neomycin (Neo) and diphtheria toxin
(DT) cassettes (Supplementary Fig. 11). An exon 4 fragment of mSt6gal1 encoding
the catalytic domain L motif was inserted between two loxP sites in the targeting
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vector. Eighty micrograms of linearized targeting vector was electroporated into a
C57BL/6 embryonic stem (ES) cell line (B6J-S1UTR line), and G418-resistant
transfectants (300 mgml 1) were selected. ST6Gal1-ﬂoxed allele-containing clones
were screened by three patterns of PCR for homologous recombination. Chimera
mice were generated by aggregation of ST6Gal1-ﬂoxed allele-containing ES cells
with ICR mouse embryos and by transfer into surrogate mice. Chimera mice were
mated with C57BL/6 mice, and the genotypes of the offspring were screened for the
ST6Gal1-ﬂoxed allele. Heterozygous ST6Gal1f/þ mice were mated with Flp mice to
delete the neo cassette. Finally, they were crossed with AID-Cre mice to establish
ST6Gal1f/f AID-Cre mice. For CIA study, both male and female mice (12–17-week
old) were used.
Separation and puriﬁcation of serum antibodies. CCP1 (HQCHQESTXGRSR
GRCGRSGS, circled between two cysteines, X: citrulline) and Arg-control peptide
(HQCHQESTRGRSRGRCGRSGS, circled between two cysteines) were purchased
from Biologia Co. (Nagoya, Japan). Chicken or bovine type II collagen (Col II) and
human ﬁbrinogen (Fib) were purchased from Sigma-Aldrich (St Louis, MO, USA).
The above-described antigens were conjugated to CNBr-activated Sepharose 4B
(GE Healthcare Ltd.) according to the manufacturer’s protocol. After ammonium
sulfate precipitation, human and mouse sera were loaded on the columns.
Column-binding antibodies were eluted by 0.17M glycine-HCI (pH 2.7).
Non-binding fractions were also collected as ﬂow-through and then further
loaded on HiTrap Protein G columns (GE Healthcare Ltd.) for IgG puriﬁcation.
The purity of IgG fractions was conﬁrmed by ELISA. To collect CCP2- and
Col II-binding antibodies for western blotting analysis, 50 ml (for CCP2) and 1 ml
(for Col II) of mouse serum were incubated in CCP2-coated plates (MBL, Nagoya,
Japan) or Col II-coated (10mgml 1) plates overnight at 4 C. After washing with
phosphate-buffered saline (PBS), bound antibodies were eluted with 0.1M glycine
pH 2.7 and neutralized with 1M Tris-HCI pH 9.0. The amount of eluted antibodies
was evaluated by western immunoblotting analysis. Original images are presented
in Supplementary Fig. 20.
ELISA. To quantitate the amounts of antibodies, plates were coated with
10mgml 1 Fib (Sigma-Aldrich), 10mgml 1 Col II (Sigma-Aldrich), 20 mgml 1
CCP1, 20 mgml 1 Arg-control peptide, 5 mgml 1 anti-mouse IgG F(ab)2 frag-
ments (Sigma-Aldrich), or 5 mgml 1 anti-human IgG F(ab)2 fragments (Sigma-
Aldrich) in 0.1M carbonate buffer (pH 9.0) overnight at 4 C. After blocking with
1% BSA in PBST (PBS containing 0.1% Tween-20), serially diluted sera or puriﬁed
IgGs were added to each well and the amount of bound antibodies was detected
using HRP-conjugated secondary antibodies. Antibodies used for secondary anti-
bodies were as follows: goat anti-mouse IgG-HRP (SouthernBiotech., Birmingham,
AL, 1030-05), goat anti-mouse IgG2c-HRP (SouthernBiotech, 1090-05) and goat
anti-human IgG-HRP (SouthernBiotech, 2040-05).
Collagen-induced arthritis. Complete Freund’s adjuvant (CFA) was prepared by
resuspending 5mg of desiccated Mycobacterium tuberculosis H37Ra debris
(BD Biosciences, San Jose, CA, USA) in 1ml of incomplete Freund’s adjuvant
(BD Biosciences). Col II (2mgml 1), from either bovine or chicken, was
emulsiﬁed with CFA (Col II:CFA¼ 1:1) and then intradermally injected twice at
the base of the tail at intervals of 4 weeks. Mice were monitored daily for swelling of
limbs for at least 28 days and serum samples were collected at day 7 or 14 after
boosting.
Enforced sialylation of mouse monoclonal IgG. ACC4 and M2139 hybridomas
secreting mouse ACPA (IgG1) and anti-Col II (IgG2b) mAb, respectively, were
provided by R. Holmdahl (Lund University). 1E11 hybridoma secretes mouse IgG1
mAb against inﬂuenza hemagglutinin. This hybridoma was established in our
laboratory from BALB/c mice which were hyperimmunized with H3N2 inﬂuenza
virus (X31 strain). Both mSt6gal1 and mB4galt1 cDNAs were transfected into
ACC4, M2139 and 1E11 hybridomas by using the retrovirus system, in which
pMXs-IRES-EGPR/pMSCV-IRES2-DsRed express2 vectors and GP2-293 packa-
ging cells were used. GFP- and DsRed-positive hybridoma cells were sorted at least
twice by using FACS Aria II (BD Biosciences), and the culture supernatant of
puriﬁed hybridomas was subjected to IgG puriﬁcation. The quality and quantity of
puriﬁed IgGs were conﬁrmed by Coomassie brilliant blue staining of SDS–PAGE
(polyacrylamide gel electrophoresis) gels and ELISA.
Lectin blotting analysis of IgG Fc. Puriﬁed IgG (5mg) was incubated in digestion
buffer (10mM EDTA, 10mM cysteine in PBS (pH 7.4)) with 0.25 mg of papain
(Sigma-Aldrich) for 2 h at 37 C. Digested IgGs were separated by 10% SDS–PAGE
(IgGs, 1.25 mg per lane for lectin blotting; 100 ng per lane for western blotting), and
transferred onto polyvinylidene diﬂuoride membranes by semi-dry electrophoresis.
For western or lectin blotting, the membranes were incubated with either goat anti-
mouse IgG-HRP (Cell Signaling Technology Japan, K.K., Tokyo, Japan, #7076) or
biotin-conjugated lectin (Vector Laboratories, Inc., Burlingame, CA). Terminal
a2,6 sialic acid (Sia), b1,4 galactose (Gal), N-acetylglucosamine (GlcNAc), and
a-linked mannose (aMan) were detected by SNA (B-1305), ECL (B-1145), GSL II
(B-1215) and ConA (B-1005S) lectin, respectively.
PNGase F treatment. Puriﬁed IgGs (10 mg) from ACC4 hybridomas were
digested by papain. Digested IgGs were denatured by heating at 100 C for 10min
in presence of 1% SDS. Denatured IgGs were neutralized by Nonidet P-40 and
incubated with or without 1 unit per ml PNGase F (Roche) for 24 h at 37 C. Then,
PNGase F-treated IgG was subjected to western or lectin blotting as described
above.
Collagen antibody-induced arthritis. DBA/1 mice (10–12-week old) were
administered by intraperitoneal injections of both ACC4 and M2139 (4.5mg each)
with or without sialylation. To induce arthritis, the mice were intraperitoneally
injected with 25 mg of LPS from Escherichia coli 055:B5 (Sigma-Aldrich) 5 days
later. Mice were monitored daily for swelling encompassing the ankle, foot and
digits or ankylosis of the limb for at least 28 days and serum samples were collected
at day 7 after boosting.
Histological analysis of knee joints. Naive and arthritis-induced mice were
sacriﬁced and perfused with PBS, followed by 4% paraformaldehyde (PFA) in PBS.
All limbs were removed and post-ﬁxed with 4% PFA in PBS for 1 week,
decalciﬁed in 10% EDTA in Milli-Q water (pH 7.4) for 30 days at 4 C, dehydrated
in a graded ethanol series, and embedded in parafﬁn. Blocks were cut into
serial sagittal sections (4.5 mm). Each section was stained with hematoxylin/eosin
(HE) or Safranin O/Fast Green for cartilage staining and observed by light
microscopy.
LC-ESI-MS analysis. Aliquots of IgG fractions (5–10 mg) were carboxymethylated
and digested by trypsin. Digested samples from RA patients and mouse model were
analysed by an LC-ESI-MS system consisting of a Paradigm MS4 (Michrome
Bioresources, Inc.) or an EASY-nLC 1000 (Thermo Scientiﬁc) HPLC system and
Orbitrap Elite hybrid (Thermo Scientiﬁc, Inc.) or Q Exactive (Thermo Scientiﬁc,
Inc.) MS system equipped with a nanoESI ion source, and digested samples from
ACC4, M2139 and 1E11 hybridoma IgGs were analysed by an LC-ESI-MS
system consisting of an EASY-nLC 1000 (Thermo Scientiﬁc) and Orbitrap Fusion
Tribrid mass spectrometer (Thermo Scientiﬁc, Inc.). Details of the method used for
LC-ESI-MS analysis are described in Supplementary Methods.
MALDI-TOF-MS analysis. Samples for MALDI-TOF-MS were prepared from
10 mg of puriﬁed IgGs from CIA-induced ST6Gal1f/f AID-Cre, ST6Gal1f/f, AID-Cre
and C57BL/6j mice and total serum IgG from ST6Gal1 KO mice by BlotGlyco
(Sumitomo Bakelite Co., Tokyo, Japan) according to the manufacturer’s protocol55.
Samples were analysed by MALDI-TOF system by using an Autoﬂex III TOF/TOF
mass spectrometer equipped with a reﬂector and controlled by the FlexControl 3.0
software package (Bruker Daltonics GmbH, Bremen, Germany). Details of the
method used for MALDI-TOF-MS analysis are described in Supplementary
Methods.
Real-time RT–PCR. The indicated tissues were isolated from mice and
homogenized in Trizol (Life Technologies). Total RNA was extracted from tissues
with Trizol according to the manufacturer’s protocol and then reverse-transcribed
into cDNA by using M-MLV Reverse Transcriptase (Life Technologies) and oligo
dT primer (Sigma-Aldrich). Real-time RT-PCR (PCR with reverse transcription)
was performed using 4 ng of RNA/cDNA per well, with F-400 from an SYBR green
qPCR kit (Finnzymes, Espoo, Finland), and Thermal Cycler PTC-20 (Bio-Rad
Laboratories, Inc., Hercules, CA, USA). The PCR conditions were as follows:
preheating for 10min at 95 C, 40 cycles of 95 C (10 s), 60 C (20 s) and 72 C
(20 s). The plate reader was set at 75 C (2 s) depending on individual primer pairs.
mSt6gal1 or mSt6gal2 cDNA vectors were used as the standard. Every sample was
measured in duplicate, and gene expression levels were analysed by using Opticon
Moniter3 software (Bio-Rad Laboratories).
Statistical analysis. Data were presented as individual donor, mouse or samples,
and mean values were presented as bars. Column graph data were shown as
mean±s.d. No statistical method was used to determine sample size. There was no
randomization of mice or samples before analysis, and the mice were selected based
on availability. No blinding was performed in this study. Donors, mice or samples
were not excluded from any of analysis in this study. Results were initially analysed
for homogeneity of variance using Bartlett’s, Hartley’s and Levene’s tests. The
Shapiro–Wilk test was used to verify that the data followed normal distribution. In
the case of data that did not meet the assumptions of homogeneity of variance or
normal distribution, non-parametric analysis was used for statistical tests.
Statistical signiﬁcance was calculated by using two-tailed Student’s t test
(parametric analysis) or Mann–Whitney test (non-parametric analysis) for two
comparison groups and one-way analysis of variance (ANOVA) followed by
Tukey–Kramer post hoc test (parametric analysis) or Steel–Dwass test (non-para-
metric analysis) for 43 comparison groups. The frequency of arthritis between
groups was analysed using two-tailed Fisher’s exact test on each day. All statistical
signiﬁcances were set at *Po0.05, **Po0.01, ***Po0.001.
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